Surrozen, Inc., a biotechnology company incorporated in Delaware on August 21, 2020. The company is committed to discovering and developing product candidates that selectively modulate the Wnt pathway (a key mediator for tissue repair), with a current strategic focus on the ophthalmology field, where Wnt signaling plays a central role in retinal vascular integrity, barrier function and tissue maintenance. Based on the pioneering work of its founders and scientific advisors in discovering the Wnt gene and its key regulators, Surrozen has made a breakthrough discovery that enables the rapid and flexible design of tissue-targeted therapies that modulate Wnt signaling. These findings form the basis of its ophthalmic product portfolio and research projects aimed at restoring tissue structure and function for serious ophthalmic diseases with unmet medical needs. Its main product candidate is an antibody-based multispecific biological agent that mimics the function of natural Wnt proteins.